重庆发文支持创新药发展，外媒称“中国制药企业正在崛起”

Group 1 - The Chinese government is supporting the high-quality development of innovative drugs by providing up to 10 million yuan in funding for eligible projects, including first-class innovative drugs, second-class improved new drugs, and biosimilars [1] - Chinese pharmaceutical companies are transitioning from raw material producers to innovative drug manufacturers, with their share in global drug research and development nearing 30%, while the share of US companies has decreased to approximately 48% [4] - The number of Chinese innovative drugs included in global conference abstracts has reached a record high this year, indicating a growing recognition of China's contributions to drug development [4] Group 2 - In the first half of this year, US and Chinese pharmaceutical companies completed 14 licensing deals worth $18.3 billion, highlighting increasing collaboration between the two markets [4] - The expiration of patents for blockbuster drugs before 2030 is creating opportunities for collaboration between US and Chinese pharmaceutical companies, as US firms need to replenish their drug development pipelines [4] - The high costs associated with drug development in the US present challenges, further opening the door for partnerships with Chinese companies [4]